VERRICA PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.87 USD | +3.31% |
|
-1.58% | -6.15% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 409.6 | 297.7 | 252.1 | 113 | 307.9 | 291.4 | - | - |
| Enterprise Value (EV) 1 | 409.6 | 297.7 | 252.1 | 113 | 307.9 | 291.4 | 291.4 | 291.4 |
| P/E ratio | -14.1 x | -6.73 x | -7.05 x | -3.82 x | -4.95 x | -4.43 x | -8.7 x | 111 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 21 x | 12.5 x | 60.1 x | 12.2 x | 4.04 x | 2.12 x |
| EV / Revenue | - | - | 21 x | 12.5 x | 60.1 x | 12.2 x | 4.04 x | 2.12 x |
| EV / EBITDA | -13.6 x | - | - | - | -4.72 x | -4.55 x | -9.56 x | -56.8 x |
| EV / FCF | -14.6 x | -9.4 x | -8.86 x | -5.96 x | -7.91 x | -4.43 x | -11.3 x | 4.29 x |
| FCF Yield | -6.86% | -10.6% | -11.3% | -16.8% | -12.6% | -22.6% | -8.89% | 23.3% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 25,775 | 25,866 | 27,519 | 41,094 | 42,065 | 42,420 | - | - |
| Reference price 2 | 15.89 | 11.51 | 9.160 | 2.750 | 7.320 | 6.870 | 6.870 | 6.870 |
| Announcement Date | 3/13/20 | 3/4/21 | 3/2/22 | 3/6/23 | 2/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 12 | 9.032 | 5.124 | 23.95 | 72.18 | 137.3 |
| EBITDA 1 | -30.02 | - | - | - | -65.23 | -64.08 | -30.5 | -5.135 |
| EBIT 1 | -30.08 | -40.18 | -30.91 | -21.3 | -65.76 | -68.94 | -33.54 | 11.81 |
| Operating Margin | - | - | -257.57% | -235.78% | -1,283.35% | -287.86% | -46.46% | 8.6% |
| Earnings before Tax (EBT) 1 | -28.21 | -42.69 | -35.08 | -24.49 | -67 | -75.47 | -38.08 | 12.3 |
| Net income 1 | -28.21 | -42.69 | -35.08 | -24.49 | -67 | -76 | -39.46 | 5.664 |
| Net margin | - | - | -292.33% | -271.11% | -1,307.47% | -317.33% | -54.67% | 4.12% |
| EPS 2 | -1.130 | -1.710 | -1.300 | -0.7200 | -1.480 | -1.552 | -0.7900 | 0.0620 |
| Free Cash Flow 1 | -28.09 | -31.68 | -28.46 | -18.95 | -38.94 | -65.8 | -25.9 | 67.9 |
| FCF margin | - | - | -237.21% | -209.83% | -759.93% | -274.75% | -35.88% | 49.44% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 1,198.88% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/13/20 | 3/4/21 | 3/2/22 | 3/6/23 | 2/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 0.431 | 0.214 | 8.319 | 0.068 | 0.037 | 0.182 | 2.917 | 1.988 | 2.651 | 4.746 | 7.007 | 9.662 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -11.77 | -8.47 | -7.41 | -9.121 | 1.448 | -6.211 | -7.089 | -11.62 | -23.92 | -23.14 | -19.86 | -18.46 | -16.78 | -14.56 |
| Operating Margin | - | - | -1,719.26% | -4,262.15% | 17.41% | -9,133.82% | -19,159.46% | -6,382.42% | -819.92% | -1,163.78% | -749.31% | -388.97% | -239.49% | -150.72% |
| Earnings before Tax (EBT) 1 | -12.83 | -9.54 | -8.47 | -10.17 | 0.083 | -5.932 | -6.589 | -10.99 | -24.8 | -24.61 | -21.07 | -19.7 | -18.35 | -16.2 |
| Net income 1 | -12.83 | -9.54 | -8.47 | -10.17 | 0.083 | -5.932 | -6.589 | -10.99 | -24.8 | -24.61 | -21.07 | -19.7 | -18.35 | -16.2 |
| Net margin | - | - | -1,965.2% | -4,751.4% | 1% | -8,723.53% | -17,808.11% | -6,038.46% | -850.26% | -1,238.13% | -794.66% | -414.97% | -261.89% | -167.64% |
| EPS 2 | -0.4700 | -0.3500 | -0.3100 | -0.3700 | - | -0.1400 | -0.1500 | -0.2400 | -0.5400 | -0.5300 | -0.4520 | -0.4080 | -0.3620 | -0.3160 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/12/21 | 3/2/22 | 5/9/22 | 8/11/22 | 11/7/22 | 3/6/23 | 5/9/23 | 8/8/23 | 11/9/23 | 2/29/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -28.1 | -31.7 | -28.5 | -19 | -38.9 | -65.8 | -25.9 | 67.9 |
| ROE (net income / shareholders' equity) | -36.5% | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | -1.100 | - | - | - | - | - | - | - |
| Capex 1 | 0.68 | 1.47 | 0.88 | 0.3 | 0.36 | 5 | 5 | 5 |
| Capex / Sales | - | - | 7.36% | 3.34% | 7.06% | 20.88% | 6.93% | 3.64% |
| Announcement Date | 3/13/20 | 3/4/21 | 3/2/22 | 3/6/23 | 2/29/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
6.87
USD
Average target price
13.6
USD
Spread / Average Target
+97.96%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.15% | 291M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- VRCA Stock
- Financials Verrica Pharmaceuticals Inc.
